Predicted disease compositions of human gliomas estimated from
  multiparametric MRI can predict endothelial proliferation, tumor grade, and
  overall survival by Diller, Emily E et al.
Predicted disease compositions of human gliomas estimated from 
multiparametric MRI can predict endothelial proliferation, tumor grade, and 
overall survival 
Emily E Diller1,2, MS, Sha Cao3, PhD, Beth Ey4, MD, Robert Lober5, MD, PhD, Jason G 
Parker1,2, PhD, 
1Department of Radiology and Imaging Sciences, Indiana University School of Medicine; 2School of 
Health Sciences, Purdue University; 3Department of Biostatistics, Indiana University School of Medicine; 
4Radiology, Dayton Children’s Hospital; 5Neurosurgery, Dayton Children’s Hospital 
Corresponding Author Info: Emily Diller, 950 W. Walnut St., Indianapolis, IN 46202, telephone: (317) 278-
9811, dillere@purdue.edu, emdiller@iu.edu   
(Preprint submitted to Journal of Neuroimaging) 
Abstract: 
Background and Purpose: Biopsy is the main determinants of glioma clinical management, but 
require invasive sampling that fail to detect relevant features because of tumor heterogeneity. The 
purpose of this study was to evaluate the accuracy of a voxel-wise, multiparametric MRI radiomic 
method to predict features and develop a minimally invasive method to objectively assess 
neoplasms.  
Methods: Multiparametric MRI were registered to T1-weighted gadolinium contrast-enhanced 
data using a 12 degree-of-freedom affine model. The retrospectively collected MRI data included 
T1-weighted, T1-weighted gadolinium contrast-enhanced, T2-weighted, fluid attenuated inversion 
recovery, and multi-b-value diffusion-weighted acquired at 1.5T or 3.0T.  Clinical experts provided 
voxel-wise annotations for five disease states on a subset of patients to establish a training feature 
vector of 611,930 observations. Then, a k-nearest-neighbor (k-NN) classifier was trained using a 
25% hold-out design. The trained k-NN model was applied to 13,018,171 observations from 
seventeen histologically confirmed glioma patients. Linear regression tested overall survival’s 
(OS) relationship to predicted disease compositions (PDC) and diagnostic age (α = 0.05). 
Canonical discriminant analysis tested if PDC and diagnostic age could differentiate clinical, 
genetic, and microscopic factors (α = 0.05).  
Results: The model predicted voxel annotation class with a Dice similarity coefficient of 94.34% 
± 2.98. Linear combinations of PDCs and diagnostic age predicted OS (p = 0.008), grade (p = 
0.014), and endothelia proliferation (p = 0.003); but fell short predicting gene mutations for 
TP53BP1 and IDH1.  
Conclusions: This voxel-wise, multi-parametric MRI radiomic strategy holds potential as a non-
invasive decision-making aid for clinicians managing patients with glioma. 
Keywords: neuro-oncology; machine learning; radiomics; glioma; multiparametric; voxel-wise; 
MRI 
1. Introduction 
Every year more than 6 per 100,000 adults in the United States are diagnosed with glioma, the 
most common malignant tumor of the central nervous system.1  For clinical purposes, the World 
Health Organization (WHO) grades gliomas I to IV, based on histologic and molecular features, 
with the worst survival associated with glioblastoma, WHO grade IV, in which only one half of 
patients survive one year after diagnosis.2 Lower grade gliomas (LGG), as defined by The Cancer 
Genome Atlas (TCGA), include WHO grades II and III gliomas and have a survival range of one 
to fifteen years.3 Grading informs various treatment protocols including resection, chemotherapy, 
radiation therapy, and long-term monitoring. Unfortunately, complete surgical resection may be 
infeasible, and both epigenetic characteristics and tumor heterogeneity may reduce sensitivity to 
chemotherapy and radiotherapy.2   
The current standard for glioma diagnosis is histopathologic evaluation after resection or 
biopsy, with refinements in tumor classification based on molecular features.  However, not all 
patients are candidates for surgery and, even with advancements in stereotaxic methods, the 
availability and quality of diagnostic tissue is constrained by procedure time, sampling error, and 
user interpretation.5, 6 Therefore, alternative non-invasive methods must be developed to 
quantitatively investigate glioma phenotypic heterogeneity, which could alter clinical management 
strategies.  
Magnetic resonance imaging (MRI) is a noninvasive imaging modality that provides critical 
information for glioma detection and diagnosis.  Routine protocols usually include the qualitative 
imaging sequences T1-weighted (T1), gadolinium contrast-enhanced T1 (T1-GD), T2-weighted 
(T2), and fluid-attenuated inversion recovery (FLAIR).7, 8 More advanced quantitative MRI 
sequences, such as diffusion-weighted imaging (DWI) and derived apparent diffusion coefficient 
(ADC) maps, have predictive potential for glioma differentiation.9 However, most studies focus on 
the power of a single MRI sequence, using measurement techniques that neglect heterogeneity.  
Radiomics is a recently defined discipline of medical imaging that utilizes quantitative 
feature extraction and machine-learning models to develop clinically significant predictions.10 
There have been many promising studies using radiomics principles for various cancers, often 
focused on anatomical locations such as breast, lung, and pancreas, with fewer focused on 
gliomas.11-14 The Brain Tumor Segmentation (BraTS), developed by Bakas et al, is a collection of 
glioma annotations based on T1, T1-GD, T2, and FLAIR MRI data, recently applied to predict 
overall survival (OS) and progression free survival (PFS) based on radiomic features.15-17 Inano 
et al used diffusion tensor imaging (DTI) in a voxel-by-voxel (voxel-wise) method to develop k-
means clusters that significantly differentiated WHO grade II from WHO grade III and IV gliomas.18 
Tian et al used multiparametric MRI data from T1, T1-GD, T2, DWI, and arterial spin labeling 
(ASL) sequences to define texture features that significantly differentiated glioma grades using a 
more complex and resource intensive support vector machine (SVM) model.19 However, the 
utilization of multiparametric MRI with a voxel-wise radiomics method for predicting glioma grade, 
genetic mutations, and prognosis has not been fully verified.  
We hypothesized that a voxel-wise radiomics method using multiparametric MRI data 
could provide phenotypic classification reflecting general tumor heterogeneity (predicted disease 
compositions, PDC), with predictive utility for glioma grade and genetic mutations. We tested this 
with a non-parametric machine learning model employing k-nearest neighbor (k-NN) in a voxel-
wise based feature vector across five MRI sequences from a publicly available data set 
(http://www.iu.edu/~mipl), with phenotype classifications defined by field experts. 
2. Methods 
2.1 Patient population 
We obtained anonymized medical data for 28 patients with histologic diagnoses of LGG (N = 14) 
or glioblastoma multiforme (GBM, N = 14) from TCGA, in which WHO grade II and III glial tumors 
were designated as LGG.3 We excluded 11 patients: five for incomplete brain coverage, and six 
for motion or artefact. Therefore, we included 17 patients (10 LGG, 7 GBM; clinical characteristics 
summarized in Table 1).  
 
2.2 Imaging Data 
We obtained pre-intervention MRI data for all 17 patients from The Cancer Imaging Archive 
(TCIA). For each we selected five sequences in the axial plane: (1) T1; (2) T2; (3) FLAIR; (4) DWI; 
and (5) T1-GD. DWI data were processed into quantitative ADC maps using a custom script that 
solved the Stejskal-Tanner equation at each voxel.20 The DWI sequences used two b values (0, 
and 1000 s/mm2) over two, four, or five directions for ten, one, and six patients, respectively. Due 
to the nature of the archive, field strength, manufacturer, and coil selection were inconsistent 
across patients. Table 2 summarizes the MRI parameters across respective sequences. 
 Lower Grade (LGG) Glioblastoma (GBM) p-value 
Demographics 
Patients 58.8% (10/17) 41.2% (7/17) N/A 
Age at diagnosis, years 
(mean ± SD) 
51.88 ±10.67 65.72 ±12.91 0.029 
Gender   0.653 
Male 60.0% (6/10) 71.4% (5/7)  
Female 40.0% (4/10) 28.6% (2/7)  
PFS, months  
(mean ± SD) 
20.75 ±13.30 4.95 ±7.51 0.003* 
OS, months 
(mean ± SD) 
34.72 ±15.74 15.04 ±1.05 0.016* 
Histologic subtype Oligoastrocytoma 
WHO II, 40% (4/10) 
Oligodendroglioma 
WHO II, 20% (2/10) 
Anaplastic oligoastrocytoma 
WHO III, 20% (2/10) 
Anaplastic astrocytoma 
WHO III, 20% (2/10) 
Glioblastoma  
WHO IV, 100% (7/7) 
N/A 
Genetic Mutation Status (Wild-type : Mutated) 
CDKN2A 9:1 3:4 0.037 
TP53 3:7 5:2 0.104 
EGFR 9:1 3:4 0.037 
NF1 7:3 6:1 0.484 
CDKN2B 10:0 3:4 0.004* 
CDK4 8:2 5:2 0.704 
TP53BP1 6:4 7:0 0.061 
IDH1 1:9 6:1 <0.0001* 
Histologic Expression Status (Not present : present) 
Endothelial proliferation 10:0 1:6 <0.0001* 
Palisading necrosis 10:0 4:3 0.021 
Table 1: Summary of clinical characteristics with Bonferroni corrected p-values.   
MR Parameter T1 T1+ T2 FLAIR ADC 
TR [ms] 
(0018, 0080) 
2315.97 ±961.99 
[500.00, 3116.00] 
2645.97 ±1028.42 
[500.00, 3236.34] 
3427.45 ±449.42 
[3000.00, 4000.00] 
10002.35 ±0.79 
[10002.00, 10004.00] 
10000.00 ±0.00 
[10000.00, 10000.02] 
TE [ms] 
(0018, 0081) 
7.81 ±2.98 
[6.36, 14.00] 
7.81 ±2.98 
[6.36, 14.00] 
92.59 ±27.17 
[22.00, 104.97] 
130.51 ±11.69 
[123.50, 155.00] 
75.45 ±7.40 
[71.80, 99.00] 
Inversion Time [ms] 
(0018, 0082) 
1084.21 ±184.37 
[860.00, 1238.00] 
1211.00 ±101.02 
[860.00, 1238.00] 
0.00 ±0.00 
[0.00, 0.00] 
2241.18 ±19.65 
[2200.00, 2250.00] 
0.00 ±0.00 
[0.00, 0.00] 
Spacing between slices 
(0018, 0088) 
4.65 ±0.79 
[3.00, 5.00] 
2.59 ±0.20 
[2.50, 3.00] 
4.65 ±0.79 
[3.00, 5.00] 
2.59 ±0.20 
[2.50, 3.00] 
4.81 ±0.75 
[3.00, 6.00] 
Acquisition matrix 
(0018, 1310) 
313.60 ±17.94 
[256.00, 320.00] 
313.60 ±17.94 
[256.00, 320.00] 
317.87 ±19.00 
[256.00, 352.00] 
311.47 ±22.52 
[256.00, 320.00] 
128.00 ±0.00 
[128.00, 128.00] 
219.73 ±11.26 
[192.00, 224.00] 
219.73 ±11.26 
[192.00, 224.00] 
219.73 ±11.26 
[192.00, 224.00] 
219.73 ±11.26 
[192.00, 224.00] 
128.00 ±0.00 
[128.00, 128.00] 
Pixel spacing 
(0028, 0030) 
0.55 ±0.18 
[0.47, 0.94] 
0.55 ±0.18 
[0.47, 0.94] 
0.55 ±0.18 
[0.47, 0.94] 
0.57 ±0.19 
[0.47, 0.94] 
1.00 ±0.23 
[0.94, 1.88] 
Slice Thickness 
(0018, 0050) 
4.65 ±0.79 
[3.00, 5.00] 
2.59 ±0.20 
[2.50, 3.00] 
4.65 ±0.79 
[3.00, 5.00] 
2.59 ±0.20 
[2.50, 3.00] 
4.81 ±0.75 
[3.00, 6.00] 
Number of Averages 
(0018, 0083) 
1.31 ±0.79 
[1.00, 4.00] 
1.31 ±0.79 
[1.00, 4.00] 
2.00 ±0.00 
[2.00, 2.00] 
1.19 ±0.75 
[1.00, 4.00] 
1.00 ±0.00 
[1.00, 1.00] 
Parameters constant across sequences: 
Field strength 2.90 ±0.39 [1.50, 3.00] 
Flip angle 90.00 ±0.00 [90.00, 90.00] 
Mean ± standard deviation; [min, max] 
Table 2: Summary of MR Sequence Settings 
 
2.3 Image Annotation 
Within our research team, a neurosurgeon and radiologist independently annotated regions of 
interest on a pre-selected T1-GD slice, after reviewing axial MRI data (T1, T2, FLAIR, ADC, T1-
GD) for each patient on a local picture archiving and communication system (PACS). We 
annotated diseased regions with high confidence (>95%) in categories of (1) pure cyst without 
necrosis, (2) necrosis, (3) tumor, or (4) edema. For regions with moderate confidence of disease 
(>50%) but unknown classification, the reader could annotate the area as “suspicious” for disease. 
We also annotated uninvolved, normal appearing regions in categories of (1) white matter (WM), 
(2) gray matter (GM), (3) cerebral spinal fluid (CSF), or (4) air.   
2.4 Image Registration and Feature Vector 
We registered each MRI sequence to its respective T1-GD scan in FSL (Analysis Group, FMRIB 
v5.0, Oxford, UK) using an affine 12-parameter model with a correlation ration cost function and 
tri-linear interpolation, spatially smoothed the data with a one-mm Gaussian filter, and normalized 
the qualitative sequences (T1, T1-GD, T2, and FLAIR) to each patient’s average normal-
appearing WM. From the annotations we created a labeled matrix of feature vectors in which each 
observation represented one voxel within an annotated region across five MRI sequences. For 
disease annotations, only voxels with agreement between our neurosurgeon and radiologist were 
included in the feature vector. The resultant matrix contained 611,930 observations (voxels) from 
fourteen patients, across five feature vectors (MRI sequences), where each observation belonged 
to one of nine classes (annotation labels).  
2.5 k-NN Radiomics Algorithm 
We developed a radiomics algorithm based on the k-NN classification model in MATLAB® 
(R2017a, The MathWorks, Inc.), with model parameters listed in Table 3. Based on exploratory 
methods, the k-NN model demonstrated comparable or higher accuracy with lower computational 
requirements compared to other parametric and non-parametric machine learning methods. Our 
model trained on a randomly selected three-fourths of the labeled observations (N = 458,948) and 
tested on the remaining one-fourth (N = 152,982). The developed radiomics algorithm then 
predicted the class of each voxel from eleven slices across five MRI contrasts as new 
observations from seventeen patients, resulting in a total of 13,018,171 class predictions. The 
predicted class slices included the disease annotation slice, and five slices superior and inferior 
to the diseased annotation slice. Next, we defined the PDC phenotypes for each classified slice 
as a distribution of percent suspicious (%Suspicious), percent edema (%Edema), percent tumor 
(%Tumor), percent cyst (%Cyst), and percent necrosis (%Necrosis).
Property Value 
N Neighbors 10 
Distance Euclidean 
Include ties False (0) 
Distance weight Equal 
Break ties Smallest 
NS Method Kdtree 
Bucket size 50 
Standardize data True (1) 
Mu [105.77, 124.69, 144.49, 67.62, 148.69] 
Sigma [134.92, 150.77, 182.78, 74.05, 219.84] 
Prior probability [0.0177, 0.0089, 0.0831, 0.0002, 0.0002, 0.1448, 0.0447, 0.5335, 0.1665] 
Table 3: Summary of kNN model parameters 
 
2.6 Statistical Analysis 
We performed statistical analyses with SPSS (IBM, Version 25), with an a priori α significance 
level of 0.05.  We tested the assumption of normality for each continuous variable and applied 
Box-Cox transformations when necessary.  We compared values of age at diagnosis, gender, 
binary genetic mutation status (CDKN2A, TP53, EGFR, NF1, CDKN2B, CDK4, TP53BP1, IDH1), 
and binary features of endothelial proliferation (EP) and palisading necrosis (PN) between LGG 
and GBM using student’s t-test.  We compared PFS and OS between groups using the log rank 
test, and tested the relationship between both PFS and OS with PDC phenotypes using linear 
regression. Although PFS and OS are censored variables, linear regression was appropriately 
applied because all cohort subjects experienced the same events. We used canonical 
discriminant analysis with a stepwise Wilk’s lambda model that included independent factors with 
F probabilities < 0.1 and a Bonferroni correction to test differentiation power of one or more 
disease components on dependent categorical factors with significant prognostic implications. 
The continuous variables included age at diagnosis and PDC phenotypes (%Suspicious, 
%Edema, %Tumor, %Cyst, and %Necrosis). The dependent variables included binary categorical 
factors of tumor grade (TCGA classification of LGG versus GBM), mutation status (wild-type 
versus mutant) of the abovementioned genes, and the histologic features of EP and PN. Genetic 
mutation status by patient is shown in Figure 1.  We computed prior probabilities based on each 
dependent variable’s group size and tested the final model with a cross-validation method. 
 
 
 
Figure 1: Selected genetic mutation status defined as wild-type (light) or mutant 
(dark) by patient and TCGA grade class. Patients above the bold black line were 
diagnosed as GBM. Patients below the bold black line were diagnosed as LGG.  
3. Results 
3.1 k-NN Radiomics Algorithm Performance and Accuracy 
The k-NN model demonstrated 97.0% average accuracy on the training data.  On the five 
diseased tissue classifications, the average accuracy was 95.61 ± 1.48%, with “Suspicious” 
having the highest performance at 98.4% and “Cyst” the poorest performance at 94.29%. Figure 
2 shows the confusion matrix between the true and predicted classes for the testing data (N = 
152,982). The Dice similarity coefficient (DSC) was calculated for each classification (Table 4). 
 
  
 
Figure 2: Radiomics algorithm k-NN Confusion Matrix. The k-NN model accuracy was 
tested using a 25% hold-out method. As observed, there is strong main axis agreement 
between the true and predicted classes. The accuracy for the entire model, including 
disease and normal tissue classes, was 97.0%. The average accuracy for the diseased 
classes was 95.61%. 
 
 Suspicious Edema Tumor Cyst Necrosis GM CSF Air WM 
Ntruth 2631 1370 12697 35 22 22212 6856 81596 25563 
Npredicted 2589 1294 12122 33 21 19943 6162 81595 24646 
DSC 96.44 94.8 95.14 94.29 91.3 91.06 90.75 100 95.36 
Accuracy 98.40 94.45 95.47 94.29 95.45 89.78 89.88 100.00 96.41 
Table 4: Dice similarity coefficient (DSC) computed for each class, based on the predicted class label and ground 
truth class label.  
 
The average DSC was 94.35 ± 2.98 across all classes, 94.39 ± 1.90 across disease classes, and 
94.29 ± 4.35 across normal tissue classes. Example expert annotations and predictions are 
shown in Figure 3. 
 
3.2 Linear Regression 
In linear regression analysis, the continuous variable %Tumor predicted OS [F(1, 15) = 7.186, p 
= 0.017] and accounted for 27.9% of the explained variability in OS. The regression equation was: 
Predicted OS=7.67-0.037(%Tumor). There was no relationship between PDC phenotypes and 
PFS. 
3.2 Canonical Discriminant Analysis 
The CDA determined that linear functions of one or more disease components differentiated the 
binary status of four out of 11 dependent categorical variables (Table 5). A linear combination of 
%Suspicious and age at diagnosis differentiated LGG from GBM with 76.5% accuracy, 85.7% 
sensitivity, and 70.0% specificity (p = 0.014). The discriminant equation to maximally separate 
discriminant score (DS) by TCGA study class was: 
DS(TCGA)=0.575(%Suspicious)-0.057(Age at Diagnosis)+2.472. The discriminant equation to 
maximally separate DS by IDH1 mutational status was: DS(IDH1)=0.040(%Tumor)-2.997. EP 
status was differentiated with 88.2% classification accuracy, 66.7% sensitivity, and 100% 
specificity by %Necrosis and Age at Diagnosis (p=0.003). The discriminant equation to maximally 
separate DS by EP status was: DS(EP)=2.479(%Necrosis)+0.066(Age at Diagnosis)-24.253.  
  
 
Figure 3: Example of expert annotations and k-NN algorithm predictions for diseased classifications suspicious, 
edema, tumor, cyst, and necrosis. 
 
4. Discussion 
Accurate glioma grading is critical for precise therapeutic planning.21 Histopathologic glioma 
grading, the diagnostic gold standard, has inherent limitations. Biopsies are often taken from 
areas of contrast enhancement that may fail to accurately characterize intratumoral heterogeneity 
 TCGA EP TP53BP1 IDH1 
Accuracy (%) 76.5 88.2 82.4 70.6 
Sensitivity (%) 85.7 66.7 50.0 70.0 
Specificity (%) 70.0 100 92.3 71.4 
PPV (%) 66.7 100 66.7 77.8 
NPV (%) 87.5 84.6 85.7 62.5 
p value 0.014* 0.003* 0.097 0.054 
Wilk's λ 0.544 0.442 0.827 0.774 
χ2 8.533 11.420 2.762 3.720 
df 2 2 1 1 
R canonical 0.676 0.747 0.416 0.476 
CDA Model Coefficients 
Suspicious 0.575 - 0.711 - 
Edema - - - - 
Tumor - - - 0.040 
Necrosis - 2.479 - - 
Age at Diagnosis -0.057 0.066 - - 
Constant 2.472 -4.253 -0.989 -2.997 
CDA Model Discriminant Score ANOVA 
Low state (-) LGG Not present Wild type Wild type 
High state (+) GBM Present Mutant Mutant 
Mean (-) 0.711 -0.791 -0.239 0.630 
95% CI (-) (0.036, 1.386) (-1.432, -0.150) (-0.829, 0.352) (-0.181, 1.440) 
Mean (+) -1.041 1.412 0.774 -0.409 
95% CI (+) (-1.848, -0.234) (0.544, 2.280) (-0.291, 1.839) (-1.087, 0.269) 
p value 0.003 0.001 0.097 0.054 
Effect Size 0.457 0.558 0.173 0.226 
Observed Power 0.912 0.981 0.382 0.500 
Table 5: Summary of Canonical Discriminant Analysis statistical findings. Accuracy, sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV) are reported in percentage. Low (-) and high (+) state 
defined for CDA to maximally separate derived discriminant scores (DS). Confidence intervals (CI) were 
determined for each state from the DS calculated by the respective CDA model coefficients. 
and tumoral infiltration.22, 23 Here we developed a voxel-wise radiomics method using 
multiparametric MRI data to PDC and their relevance to microscopic and molecular features. The 
major finding of this study is that PDC from multiparametric MRI data differentiates lower grade 
gliomas from GBM at the resolution of a single MRI voxel with accuracy, sensitivity, and specificity 
greater than or equal to 70%. 
 A unique tool for glioma research is BraTS: a multiparametric MRI data set of histologically 
confirmed LGG and GBM patients, which includes pre-intervention MRI data (T1, T2, T1Gd, 
FLAIR) registered to a universal, anatomical template (MNI-152) with manual segmentations for 
necrosis, edema, and contrast-enhancing tumor.15 However, previous studies with this have 
struggled to discriminate LGG from GBM with specificity greater than or equal to 70%.24 Here we 
created a model with multiparametric MRI data from glioma patients in the TCGA, yielding strong 
agreement between true and predicted disease classes with 95.6% and 94.4% average DSC.   
The continuous variable %Tumor inversely correlated with OS, which was worse in GBM 
compared to LGG (p = 0.016), as expected (Table 1). Although our CDA model did not find that 
%Tumor or %Necrosis predicted grade, GBM had higher %Tumor, %Necrosis, and age at 
diagnosis compared to LGG, which interestingly had greater %Suspicious (p = 0.035, 0.016, 
0.049, and 0.015, respectively), a classification defined during expert annotation as regions of 
moderate confidence for disease and potentially reflecting a more homogeneous abnormal 
compartment in LGG.28 Additionally, we found differential power between LGG and GBM by a 
linear function of %Suspicious, and age at diagnosis.  Specifically, with GBM being associated 
with a decrease in PDC Suspicious and an increase in age. Patients with GBM are generally older 
at diagnosis than patients with LGG.25-27   
The most common pattern of confusion occurred when the true disease classes “Cyst” 
and “Necrosis” were predicted as “Tumor” and “Edema,” and when “Tumor” was predicted as 
“normal-appearing GM”.  Such labeling confusion is expected, just as inter- and intra-observer 
error is unavoidable,21, 22 and we attempted to mitigate this by defining disease class ground truth 
as voxels of agreement between the independent annotation of two expert clinicians. 
Despite the promising results, this study has limitations. First, this retrospective study has 
a small sample size with variations in MRI protocols, manufacturers, and field strengths across 
different institutions. Although these variations may help support the generalizability of our 
findings, a future large-scale study is required to fully assess the generalizability of this model. 
Second, due to the limited sample size, this study applied machine learning techniques to each 
voxel as an observation across sequences resulting in a train and test feature vectors with 
randomly assigned voxels across patients. Since the voxels are randomly assigned to one of two 
feature vectors, a voxel neighboring a train voxel will be assigned to the test feature vector and 
could lead to over fitting. In the future, train and test feature vectors distributed by patient instead 
of random voxel selection should be explored. Third, the disease classification is based on 
annotation agreement between two expert readers following a common protocol. In future work, 
annotations should be collected from multiple experts following an established protocol and 
annotations of high agreement across expert readers should be used for a model.  
In conclusion, we have proposed a five-feature, voxel-wise model with five phenotype 
signature described by PDC that have potential as an imaging biomarker to differentiate 
prognostic features. Non-invasive methods to reliably classify and differentiate prognostic 
features is an important development for the advancement of glioma treatment management.  The 
results shown in this work demonstrate the promise and need for future development of computer-
aided decision making tools through multiparametric, voxel-wise radiomic algorithms. Utilizing the 
power of radiomics, gliomas may be non-invasively managed resulting in the advancement of 
treatment and care.  
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